FDA Pushes Decision on AMX0035 to September for Further Review
Note: This story was updated June 7, 2022, to note that CENTAUR is a Phase 2, not Phase 2/3, trial and that AMX0035 reduced the risk of death by 43%, instead of 44%. There also has been no indication that U.S. sites will open soon for the PHOENIX trial.